ORIC PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ORIC PHARMACEUTICALS, INC. (ORIC) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.27 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 18.27M shares, a 20.44% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 17.98M shares, a 19.39% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 15.08M shares, a 27.46% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 15.17M shares, a 30.24% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.48M shares, a 23.68% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.71M shares, a 29.47% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.05M shares, a 31.44% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.88M shares, a 30.64% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 18.27M shares 10-Q · filed 2026-08-03 | 18.27M shares 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | 17.98M shares 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | 14.48M shares 10-K · filed 2026-02-23 | |||
| 2025-09-30 | 15.08M shares 10-Q · filed 2025-11-13 | 15.08M shares 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 15.17M shares 10-Q · filed 2026-08-03 | 15.17M shares 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | 15.06M shares 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | 11.71M shares 10-K · filed 2026-02-23 | |||
| 2024-09-30 | 11.83M shares 10-Q · filed 2025-11-13 | 11.83M shares 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 11.65M shares 10-Q · filed 2025-08-12 | 11.65M shares 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | 11.51M shares 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | 9.05M shares 10-K · filed 2025-02-18 | |||
| 2023-09-30 | 9.11M shares 10-Q · filed 2024-11-12 | 9.11M shares 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 9.08M shares 10-Q · filed 2024-08-12 | 9.08M shares 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | 8.96M shares 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | 6.88M shares 10-K · filed 2024-03-11 | |||
| 2022-09-30 | 6.84M shares 10-Q · filed 2023-11-06 | 6.84M shares 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | 6.89M shares 10-Q · filed 2023-08-10 | 6.89M shares 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 6.64M shares 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 5.27M shares 10-K · filed 2023-03-16 | |||
| 2021-09-30 | 5.26M shares 10-Q · filed 2022-11-07 | 5.26M shares 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 5.21M shares 10-Q · filed 2022-08-11 | 5.21M shares 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 5.07M shares 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 4.00M shares 10-K · filed 2022-03-21 | |||
| 2020-09-30 | 3.96M shares 10-Q · filed 2021-11-08 | 3.96M shares 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | 3.95M shares 10-Q · filed 2021-08-10 | 3.95M shares 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | 21.94M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 21.96M shares 10-K · filed 2022-03-21 | |||
| 2019-09-30 | 21.53M shares 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 20.64M shares 10-Q · filed 2020-08-05 | 20.64M shares 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | 17.04M shares 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | 15.64M shares 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |